High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

Published Date: 29 Apr 2024

Over 90% of cases are undetectable, and ctDNA is promising for early recurrence detection.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chronic pain and poor sleep are troublesome bed partners.

2.

'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested

3.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

4.

Alkem introduces cetuximab under the trade name Cetuxa in India.

5.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot